Continuous Glucose MonitoringGLANCE-PDNCT07790276
Continuous Glucose Monitoring and Clinical Outcomes in Diabetes on Peritoneal Dialysis
An observational study of Continuous Glucose Monitoring and ESRD (End-Stage Renal Disease), run by Elaine Chow at 1 site in Hong Kong.
Trial summary
This prospective, multicenter observational study will evaluate glucose profiles using continuous glucose monitoring (CGM) in 100 adults with diabetes receiving peritoneal dialysis (PD) or planning to start PD within 3 months. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Continuous Glucose Monitoring, ESRD (End-Stage Renal Disease), Peritoneal Dialysis (PD)
- What is being tested?
- Continuous glucose monitoring system
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- 1 siteHong Kong
- Study dates
- 31 Aug 2026to Sep 2028
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with diabetes and stage 5 chronic kidney disease who are receiving peritoneal dialysis or are planned to initiate peritoneal dialysis within 3 months.
Who may be able to join
- Stage 5 CKD patients
- who have received PD for at least 3 months, OR
- who are planned for PD within the next 3 months.
- Age 18-80 years old
- Known history of type 1 or type 2 diabetes for at least 3 months
- Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.
Show all 10Show fewer
- Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.
- Willingness to abstain from swimming during their participation in the measurement phase.
- In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.
- Written informed consent to participate in the study provided by the patient.
Who cannot join
- Patients who are planning to switch to hemodialysis or renal transplant in the coming 3 months
- Life expectancy <6 months
- Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites
- HbA1c > 11% at enrolment
- Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential.
- Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.
Show all 10Show fewer
- Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.
- Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
- Have a known allergy to medical-grade adhesives or known hypersensitivity to any of the products used in the study.
- Have MRI scan, CT scan, or diathermy scheduled during the proposed period of sensor wearing during the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site
Department of Medicine and Therapeutics, The Chinese University of Hong Kong
Hong Kong
Elaine Chow, +85235051549, e.chow@cuhk.edu.hk
Jack Kit Chung Ng
About this study
Official title: Glycemic Assessment Based on Continuous Glucose Monitoring and Clinical Outcomes in People With Diabetes on Peritoneal Dialysis: a Multi-centered Prospective Study
This prospective, multicenter observational study will evaluate glucose profiles using continuous glucose monitoring (CGM) in 100 adults with diabetes receiving peritoneal dialysis (PD) or planning to start PD within 3 months. The study will examine associations between CGM metrics and PD regimen, glucose-lowering treatment, conventional glycemic markers, dialysis-related measures, and clinical outcomes including glycemic emergencies, hospitalizations, cardiovascular events, and mortality over 12 months.
- Conditions
- Continuous Glucose Monitoring, ESRD (End-Stage Renal Disease), Peritoneal Dialysis (PD), Diabetes Mellitus (DM)
- Being tested
- Continuous glucose monitoring system
- Medical subject headings
- Renal Insufficiency, Chronic, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous glucose monitoring systemDevice
Sibionics GS3 CGM
| Study group | Role | What they receive |
|---|---|---|
| peritoneal dialysis group | Adults with diabetes and stage 5 chronic kidney disease who have been receiving peritoneal dialysis for at least 3 months at enrollment. Receives: Device: Continuous glucose monitoring system | |
| pre-peritoneal dialysis group | Adults with diabetes and stage 5 chronic kidney disease who are planned to initiate peritoneal dialysis within 3 months after enrollment. Receives: Device: Continuous glucose monitoring system |
What is being measured
The primary outcome is the main question the study is designed to answer.
Continuous glucose monitoring-derived metrics
CGM derived time in ranges
Measured: During period of 14 day CGM wear
Secondary outcomes (9)
HbA1c
HbA1c by venous blood
Measured: Baseline to end of study period month 12
24-hour dialysate and ultrafiltration volume
24-hour dialysate and ultrafiltration volume,
Measured: Baseline through to month 12
Residual renal function
Defined by 24-hour urine volume
Measured: From baseline through 12 months
Hospitalization for hyperglycemic or hypoglycemic emergencies
Incidence of hospitalization due to hyperglycemic or hypoglycemic emergencies during follow-up
Measured: From baseline through 12 months
Hospitalizations, cardiovascular events, and all-cause mortality
Incidence of all-cause hospitalization, major cardiovascular events, and all-cause mortality during follow-up
Measured: From baseline through 12 months
Dietary intake during CGM wear
Dietary intake assessed using a 3-day food diary
Measured: During the 14-day CGM wear period
Health-related quality of life
EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) overall score
Measured: Baseline
Quality of life specific to kidney disease
Kidney Disease Quality of Life-36 questionnaire (KDQOL-36) total score
Measured: Baseline
CGM user satisfaction
Total score from 10-item CGM user satisfaction questionnaire
Measured: Baseline and month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2026
- Study start31 Aug 2026 (estimated)
- Primary completionJun 2028 (estimated)
- Study completionSep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Continuous Glucose MonitoringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Elaine Chow
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Elaine Chow, Chinese University of Hong Kong
- Investigators
- Elaine Chow, Principal investigator, Department of Medicine and Therapeutics, The Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07790276
- Sponsor's protocol ID
- GLANCE-PD
- Acronym
- GLANCE-PD
- Status last verified
- Aug 2026
- First submitted
- 21 Aug 2026
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No